![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accesswire.com/639869/Aytu-BioPharma-Adds-Late-Stage-Pediatric-Onset-Rare-Disease-Asset-to-Development-Pipeline-from-Rumpus-Therapeutics
https://www.accesswire.com/638540/Aytu-BioPharma-Divests-US-Rights-to-NatestoR-to-Acerus-Pharma
https://www.biospace.com/article/releases/aytu-bioscience-announces-close-of-merger-with-neos-therapeutics/?s=79
https://www.biospace.com/article/releases/aytu-bioscience-announces-close-of-merger-with-neos-therapeutics/?s=79
https://www.biospace.com/article/releases/aytu-bioscience-and-neos-therapeutics-announce-special-meetings-of-stockholders-related-to-proposed-merger-to-be-held-on-march-18-2021/?s=79
https://www.biospace.com/article/releases/aytu-bioscience-announces-closing-of-28-75-million-bought-deal-offering-and-full-exercise-of-underwriter-s-option-to-purchase-additional-shares/#:~:text=(NASDAQ%3AAYTU)%2C%20(,Company%2C%20which%20includes%20the%20full
https://www.accesswire.com/620494/Aytu-BioScience-Announces-100-Million-Bought-Deal-Offering
https://www.globenewswire.com/news-release/2020/12/10/2143034/0/en/Aytu-BioScience-and-Neos-Therapeutics-Announce-Definitive-Merger-Agreement-Creating-a-Combined-100M-Revenue-Specialty-Pharmaceutical-Company.html
https://www.globenewswire.com/news-release/2020/12/10/2143034/0/en/Aytu-BioScience-and-Neos-Therapeutics-Announce-Definitive-Merger-Agreement-Creating-a-Combined-100M-Revenue-Specialty-Pharmaceutical-Company.html